8-K: Dare Bioscience Secures Nasdaq Plan Approval Amidst Delisting Concerns

Dare Bioscience, Inc. announced that the Nasdaq Hearings Panel approved its modified multi-step plan to regain compliance with listing requirements, though the company faces a critical deadline of August 12, 2025, to avoid delisting.

Summary

• Dare Bioscience, Inc. received a letter from The Nasdaq Stock Market LLC on June 24, 2025, informing them that the Nasdaq Hearings Panel approved their modified multi-step plan to regain compliance with listing rules.
• The company has been non-compliant with Nasdaq Listing Rule 5550(b) since August 2024, which requires either stockholders' equity of at least $2.5 million or a minimum market value of listed securities of $35.0 million.
• The approved plan requires Dare to demonstrate compliance with either the Stockholders Equity Rule or the Minimum MVLS Rule by July 31, 2025.
• If compliance is achieved via the Minimum MVLS Rule, Dare must publicly disclose transactions undertaken to increase stockholders' equity and provide updated equity figures.
• The company also needs to provide the Panel with updates on fundraising plans and updated income projections for the next 12 months.
• The conditional continued listing period granted by the Panel remains August 12, 2025, and there are no assurances that Dare will successfully execute its plan or meet the compliance requirements by the deadlines.

Sentiment

Score: 4

Explanation: The approval of the compliance plan provides a clear path forward and avoids immediate delisting, which is a positive. However, the company remains non-compliant, faces significant deadlines, and there are no assurances of success, indicating continued high risk and financial pressure.

Positives

• The Nasdaq Hearings Panel approved Dare Bioscience's modified multi-step plan to regain compliance, providing a defined path forward.
• The conditional continued listing period until August 12, 2025, remains in effect, offering the company time to execute its plan.

Negatives

• Dare Bioscience has been non-compliant with Nasdaq Listing Rule 5550(b) since August 2024, indicating a prolonged financial challenge.
• The company faces a critical deadline of July 31, 2025, to demonstrate compliance with either the $2.5 million Stockholders Equity Rule or the $35.0 million Minimum Market Value of Listed Securities Rule.
• Failure to execute the plan or regain compliance by August 12, 2025, could result in the delisting of common stock and suspension of trading on Nasdaq.
• There are no assurances that the company will be successful in executing its plan or satisfying the compliance rules.

Risks

• Failure to successfully execute the approved multi-step plan to regain compliance with Nasdaq Listing Rule 5550(b).
• Inability to satisfy either the Stockholders Equity Rule ($2.5 million) or the Minimum Market Value of Listed Securities Rule ($35.0 million) by July 31, 2025, or August 12, 2025.
• Potential delisting of common stock and suspension of trading on Nasdaq if compliance is not regained, even before the August 12, 2025, deadline.
• The Nasdaq Hearings Panel reserves the right to reconsider the terms of the extension based on any adverse event, condition, or circumstance.
• Limited demand for common stock, substantial impairment of ability to raise additional capital, and adverse effect on the market price and trading efficiency of common stock due to non-compliance or delisting.
• Risks and uncertainties related to Dare's ability to raise additional capital to increase its stockholders' equity.

Future Outlook

Dare Bioscience's future outlook is contingent on its ability to successfully execute its approved multi-step plan to regain compliance with Nasdaq listing rules. The plan includes demonstrating compliance with either the $2.5 million Stockholders Equity Rule or the $35.0 million Minimum MVLS Rule by July 31, 2025. The company also plans to provide updates on fundraising efforts and updated income projections for the next 12 months to the Nasdaq Hearings Panel. However, there are no assurances that the company will achieve these objectives by the final conditional listing deadline of August 12, 2025.

Management Comments

• "Dare cautions you that all statements, other than statements of historical facts, contained in this report, are forward-looking statements."
• "Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Dars actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements."
• "Forward-looking statements are based upon Dars current expectations and involve assumptions that may never materialize or may prove to be incorrect."
• "Dar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law."

Industry Context

This announcement is specific to Dare Bioscience's compliance with Nasdaq listing requirements and does not directly reflect broader industry trends. However, maintaining listing status is crucial for biotechnology companies like Dare to access capital markets and maintain investor confidence, which is a common challenge for development-stage companies.

Stakeholder Impact

• Shareholders face significant risk of delisting and suspension of trading, which could severely limit demand for common stock, impair the company's ability to raise capital, and adversely affect the market price and trading efficiency. The approval of the plan offers a temporary reprieve and a path to compliance.
• Employees may face potential impact on job security and company stability if delisting occurs.
• Creditors may face increased risk if the company's financial health deteriorates further due to delisting or inability to raise capital.
• Customers/Partners may experience potential impact on confidence and ongoing relationships if the company's financial stability is perceived as precarious.

Next Steps

• Dare Bioscience must demonstrate compliance with either the Stockholders Equity Rule ($2.5 million) or the Minimum MVLS Rule ($35.0 million) on or before July 31, 2025.
• If compliance is achieved via the Minimum MVLS Rule, the company must publicly disclose transactions undertaken to increase stockholders' equity and provide an indication of stockholders' equity following such transactions.
• Dare must provide the Nasdaq Hearings Panel with updates and information on its fundraising plans.
• Dare must provide the Nasdaq Hearings Panel with updated income projections for the next 12 months.
• The company must regain and maintain compliance with Nasdaq listing requirements by August 12, 2025, to avoid delisting.

Key Dates

Keywords

Dare Bioscience, Nasdaq, Delisting, Compliance, Stockholders Equity, Market Value of Listed Securities, 8-K Filing, Biotechnology, Pharmaceuticals, Corporate Governance, Financial Health, Capital Market